VivoSeq
Other

GVHD

1

Pipeline Programs↗

1

Active Trials↗

2

Companies Involved↗

GvHD is an early-stage landscape with 1 program across 2 companies. The most active players are Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), Takeda.

Intelligence

Pipeline Metrics

Competitive Density

14/100

Pipeline Velocity

6/100

Mech. Concentration

100/100

Completion Rate

43/100

Attrition Rate

44/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

C

Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

1 program

Phase 2Takeda logo

Takeda

0 programs

Preclinical

Pipeline

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 21

Vorinostat

Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 3
No programs
Approved
No programs

Analysis

Trial Status

9

clinical trials

Terminated3 · 33%
Completed3 · 33%
Withdrawn1 · 11%
Unknown status1 · 11%
Not yet recruiting1 · 11%

Clinical Trials

Trial Activity

9 trials

Use of Vorinostat as GVHD Prophylaxis in Children, Adolescents, and Young Adults With Non-Malignant Disorders Undergoing Allogeneic Blood and Marrow Transplantation
Not yet recruiting·—·Phase 2·NCT06995521·55 enrolled
BMT Autologous MSCs for GvHD
Completed·EEmory University·Phase 1·NCT02359929·11 enrolled
Dose Finding Study of Vedolizumab for GvHD in Participants Undergoing Allogeneic HSCT
Completed·Takeda logoTakeda·Phase 1·NCT02728895·24 enrolled
Dietary Manipulation of the Microbiome-metabolomic Axis for Mitigating GVHD in Allo HCT Patients
Completed·UUniversity of Michigan Rogel Cancer Center·Phase 2·NCT02763033·107 enrolled
Ruxolitinib In GvHD
Terminated·PProf. Dr. Nikolas von Bubnoff·Phase 2·NCT02396628·22 enrolled
In-Vivo Activated T-Cell Depletion to Prevent GVHD
Terminated·IIndiana University·N/A·NCT00594308·10 enrolled
Preemptive Therapy of GVHD
Terminated·UUniversity of Calgary·Phase 2·NCT01994824·70 enrolled
Rituximab for GVHD
Withdrawn·—·Phase 2·NCT00578591
Ikervis for DED Due to GVHD Post Allo-HSCT
Unknown status·SSingapore Eye Research Institute·Phase 4·NCT04636918·40 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)